Lv1
40 积分 2022-07-07 加入
Estimation of Absorbed Doses of Indigenously Produced “Direct-route” Lutetium-177-[ 177 Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [ 177 Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles
15天前
已完结
A dosimetric comparison of systemic peptide receptor radionuclide therapy and intra-arterial peptide receptor radionuclide therapy in patients with liver dominant gastroenteropancreatic neuroendocrine tumours
15天前
已关闭
177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors
15天前
已完结
177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors
15天前
已完结
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
1个月前
已完结
Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer
6个月前
已完结
Camrelizumab and apatinib in Chinese patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer: an exploratory open-label, single-arm trial
8个月前
已完结
Combination Radiopharmaceutical Therapy and Radiotherapy for Thyroid Cancer: Dosimetry-Driven Precision Medicine
8个月前
已关闭
Quantitative Deauville Scoring to Uncover Prognostic Information from 18F-FDG PET–Based Response Assessment: Data from the EuroNet-PHL-C1 Trial
1年前
已关闭
Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy
1年前
已关闭
皖公网安备34019202002308
